About Biofrontera (NASDAQ:BFRA)
Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BFRA
CUSIPN/A
Phone49-02-1487-6320
Debt
Debt-to-Equity Ratio2.63%
Current Ratio5.50%
Quick Ratio4.40%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$6.78 million
Price / Sales45.68
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees125
Outstanding Shares22,120,000
Biofrontera (NASDAQ:BFRA) Frequently Asked Questions
What is Biofrontera's stock symbol?
Biofrontera trades on the NASDAQ under the ticker symbol "BFRA."
When is Biofrontera's next earnings date?
What price target have analysts set for BFRA?
1 equities research analysts have issued twelve-month target prices for Biofrontera's stock. Their forecasts range from $19.00 to $19.00. On average, they anticipate Biofrontera's share price to reach $19.00 in the next year. View Analyst Ratings for Biofrontera.
Who are some of Biofrontera's key competitors?
Some companies that are related to Biofrontera include BeyondSpring (BYSI), Rhythm Pharmaceuticals (RYTM), Ziopharm Oncology (ZIOP), AC Immune (ACIU), Arrowhead Pharmaceuticals (ARWR), Rigel Pharmaceuticals (RIGL), Geron (GERN), Clementia Pharmaceuticals (CMTA), Odonate Therapeutics (ODT), Achaogen (AKAO), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Kura Oncology (KURA), TiGenix - American Depositary Shares (TIG), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI) and Dicerna Pharmaceuticals (DRNA).
Who are Biofrontera's key executives?
Biofrontera's management team includes the folowing people:
- Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 62)
- Mr. Thomas Schaffer, CFO & Member of Management Board (Age 55)
- Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 50)
When did Biofrontera IPO?
(BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.
When did the company's quiet period expire?
Biofrontera's quiet period expired on Monday, March 26th. Biofrontera had issued 1,215,000 shares in its IPO on February 14th. The total size of the offering was $12,004,200 based on an initial share price of $9.88. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Has Biofrontera been receiving favorable news coverage?
News articles about BFRA stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biofrontera earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Biofrontera?
Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biofrontera's stock price today?
One share of BFRA stock can currently be purchased for approximately $14.00.
How big of a company is Biofrontera?
Biofrontera has a market capitalization of $309.72 million and generates $6.78 million in revenue each year. The company earns $-11,700,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Biofrontera employs 125 workers across the globe.
How can I contact Biofrontera?
Biofrontera's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 49-02-1487-6320 or via email at [email protected]
MarketBeat Community Rating for Biofrontera (BFRA)
MarketBeat's community ratings are surveys of what our community members think about Biofrontera and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biofrontera (NASDAQ:BFRA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Biofrontera in the last 12 months. Their average twelve-month price target is $19.00, suggesting that the stock has a possible upside of 35.71%. The high price target for BFRA is $19.00 and the low price target for BFRA is $19.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | N/A | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.00 | $19.00 | N/A | N/A |
| Price Target Upside: | 35.71% upside | N/A | N/A | N/A |
Biofrontera (NASDAQ:BFRA) Consensus Price Target History
Biofrontera (NASDAQ:BFRA) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/9/2018 | Benchmark | Initiated Coverage | Buy | $19.00 | High |  |
(Data available from 4/21/2016 forward)
Biofrontera (NASDAQ:BFRA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biofrontera (NASDAQ BFRA) Insider Trading and Institutional Ownership History
Biofrontera (NASDAQ BFRA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Biofrontera (NASDAQ BFRA) News Headlines
| Source: |
|
Biofrontera (NASDAQ:BFRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Biofrontera (NASDAQ BFRA) Stock Chart for Saturday, April, 21, 2018
Loading chart…
